Member Info for The_Paladin

I continue to believe in CapAI’s future potential. However, I am puzzled by the continued mid-level (£1000+) sales, which have been ongoing for well over a year. Is this still linked to the company’s initial funding structure? If so, when will it end?

With a webinar set for Friday afternoon to demonstrate CapMedia’s comprehensive suite of media “creator”applications, one might now expect more market interest? However, the steady selloff continues, apparently uninterrupted by a reiterated optimistic piece of information ?

I fully understand Prof Nag’s measured small team approach to CapMedia’s product launches. So far, they have not captured investor interest. The original buying frenzy was to do with Prof Nag’s involvement, with no added substance to it? Perhaps if he had come on board with a product launch in situ, we would be in a different position today?

I look forward to Friday’s webinar. In particular, whether there will be additional substance to stimulate more interest next week? I appreciate that it may take some time before sales and revenue data is available?

Otherwise, we will need to wait for the launch of a CapMedical project. Prof Nag’s is substantially involved both as a director and ans an investor in this sphere. It will be interesting to see which product he will select to finally launch CapMedical?

GLA.

The RNS is also backed up by recent LinkedIn messages from Claire L. in her roles as Author 42 writing assistant, and growth hacker. She will probably be present in Friday’s webinar.

Below is a recent message. Note that you need to be signed in to LinkedIn to view it.

https://www.linkedin.com/posts/yanbing-lu_one-of-the-cool-features-is-market-analysis-ugcPost-7469810174770413568-zq4_/?utm_source=share&utm_medium=member_ios&rcm=ACoAAFkZSG4BdxpM6GmnCyXnIP2qbL5EnrbABqc

GLA.

This forum regularly receives comments alleging how unnecessary Author 42 is? The doubters purport that the same result could be achieved using a generalised AI engine to achieve a similar result? These individuals are welcome to their opinions. In the general sense, I would disagree from a wider standpoint.

I have subscribed to iPhone Apps for several years to simplify my lifestyle. For example, for many years, I used a simple spreadsheet, which I updated manually on a daily basis to keep track of my finances. Nowadays, I use a high level app, with an annual subscription fee, which automatically sources transactions from a number of banking apps, and updates share prices from stock exchanges at the end of each trading day. The results are instantly updated on multiple devices. My choice, but one that removes an onerous task and creates additional discretionary time.

The same applies to Author 42 in my view. Claire Lu, who worked on growth hacking for R42, and is involved in the Author 42 project, recently posted the following general comment. This validates using an app like Author 42 to simplify writing experiences in various genres. This allows authors to concentrate on their projects, and avoids having to create crude approximations to the multiple aspects of A42 beforehand, and while writing their books? My view, and one which the dissenters will no doubt disagree with.

https://www.linkedin.com/posts/yanbing-lu_one-of-the-most-cited-posts-in-rwriting-ugcPost-7468438484060409857-NwGu/?utm_source=share&utm_medium=member_ios&rcm=ACoAAFkZSG4BdxpM6GmnCyXnIP2qbL5EnrbABqc

GLA.

Thank you for sharing Crownos. Your points also mirror my thoughts about the “launch”, which apparently didn’t happen as specified in last month’s RNS?

Prof Nag was also vague about the imminent CapMedia product launches during his recent online presentation to investors. Even more so about the CapMedical strategy. Does this even exist yet? It is little wonder that the share price has been so underwhelming over the last year?

The update shared by Crownos gives us some aspiration. However, it is high time for the company to get a grip. Matters are not going to improve based on the vague and incorrect information recently supplied by Prof Nag. CapAI needs someone with a business focus to take charge and add a strategy with dated targeted outcomes to the nebulous information provided by the company.

GLA.

I was under the impression that CapAI is not an AIM market stock? Didn’t it successfully transition from the AIM market to LSE's Main Market in May 2025?

Unfortunately, no relevance whatsoever - in my view that is? Other than the fact that Prof Nag has so many projects in situ that he has insufficient time for CapAI?

There has been no discernible progress since the company was re-formatted last year. With the summer months looming, it is more usually than not the time where very little happens with most small companies.

Should this prove to be the case, I agree with Goodlife in that the share price will continue to drift downwards with nothing to sustain, or increase it.

GLA. We will need it!

@scottyboy1966

The “mad professor” that you mentioned is now associated with a small company called Kirkstall (not one of my investments). Here is an account of his latest project.

“The programme is led by Professor Gareth Cave of NTU's School of Science and Technology and aims to create a microfluidic 'tumour on a chip' system capable of mimicking the key features of the human brain environment in which glioblastoma develops - the most aggressive form of brain cancer in adults.”

Only mentioned because in my view, Prof Nag is several levels above Prof Cave both in his reputation and his accomplishments. However, Prof Nag’s involvement in CapAI is minimal. It would be good to see more of his input in the near future.

@MissSmith @ElMagico

A good point. The company are by now so very far behind their original projections for Author 42. Surely they are no longer viable without sales and revenue data to justify the process?

The RNS that encouraged me just over 3 weeks ago has also turned out to be a major disappointment. Statements were made concerning the hard launch of Author 42, and the beta trialling of its two companion apps. Nothing further has emerged since then.

Meanwhile Prof Nag continues to put out messages on his other initiatives, as the CapAI share price tumbles back to ground zero. The Warrant holders continue to accrue major benefit, while those of us who invested in the company are wondering why nothing is emerging from a reformatted company now in its second year of trading?

Sadly, the warrant selling aspect has dampened the share price since I have been invested. I wouldn’t have contemplated investing so soon had I been able to work that one out earlier. It is disappointing that it continues to dampen the share price to low levels.

The dearth of concrete news is also a major factor. It is all good and well to inform the market concerning the hard launch of Author 42, and the upcoming trialling of its two companion apps. Investors came on board at this point, expecting imminent further updates. When it was apparent that this wasn’t happening anytime soon, the mass exodus quickly followed to accompany the warrant sales.

We are almost back to square one prior to the Author 42 update. I am surprised that, after a year, Professor Nag isn’t doing better? Although this all takes time, I would have expected more definitive information concerning Author 42 sales and revenues by now?

I should add that Prof Nag’s schedule ( from his Linked In contributions) is as hectic as ever. Perhaps someone else needs to take the lead with CapAI if we are to make any progress in the short to mid term. I shall remain invested for the long term, although I did expect more progress following the last strategy update,

GLA.

I am very pleased with the “hidden” progress already made by the Author 42 team. Just a few weeks ago, searching for “Author 42” yielded all sorts of obscure information. These included books published decades ago, and little known films all of which included the term in some form or other. Today, searching for Author 42 takes me directly to the product website. Also listed are financial articles relating to CapAI’s development of the product since it was first announced. The irrelevant references are no longer present on the first page. This is exactly how things should be as a precursor to the next imminent announcement from Prof Nag.

More information about Movie 42 and Gamer 42 should be with us shortly. When I messaged Jayne Lytel last weekend to congratulate her on Author 42’s launch, her reply emphasised that it was very much a team effort, and that there would be “ iterations and new features” to follow.

I also received a positive message from Jack Allardyce in response to my comment about a small error on the CapAI website, which has since been corrected. The fact that key members of staff and directors respond to investors’ comments speaks volumes about their involvement and level of interest in their work. I was not expecting a reply to my messages, as I didn’t ask any questions.

It has been a good week to date, and we are still waiting for further news about the full launch of Author 42, and the introduction of the beta versions of Gamer 42 and Movie 42 for trialling, as was the case for Author 42.

( Does anyone know the significance of the “42” brand association with Prof Nag?).

There is a long road ahead with CapAI, but it is good to have taken the first steps with the full introduction of Author 42.

GLA.

@HerefortheComedy

I have, and had to sign out to read your previous posts. However, we are now notified in our LSE personal space, whenever there is a mention from another contributor. It would be preferable on both sides if you were to kindly reciprocate and filter my comments!

@LewyLewis11

Agreed for 50K a shares dummy sell. For a 500K shares sell, I am now offered 1.475p.

@HerefortheComedy

Whatever your gripe with my contributions, get over it and grow up. Your offensive language directed at an individual does you no credit. Your moniker however fits in with the fact that you are a total joke.

@Crownos

You are probably correct? My subsequent contribution with information from Companies House contradicted the AI generated statement. I should add that the Bid had dropped to 1.44p when I last tried to execute a dummy sell. Something is going on to effect such an abrupt change in today’s trading pattern?

Can still sell, but 1.44p now offered for a 500K shares dummy sell. There has been an abrupt change in the trading pattern. No doubt we will hear something this afternoon.

The AI generated statement, which was in my last contribution does not contain the information stated on CAPAI’s U.K. Companies House file namely:

“Next accounts made up to 30 September 2026

due by 31 March 2027.

Last accounts made up to 30 September 2025.”

My quick search gave this response;

As of April 29, 2026, there are reports that trading for CapAI (CPAI) shares has been halted/stopped on the London Stock Exchange (LSE). While some sources still list normal trading status, user reports on trading platforms like T212 indicate a halt. This appears related to reporting delays rather than a permanent suspension.

London Stock Exchange

Why is trading halted?

Delayed Financial Results: CapAI (CPAI) announced it will not meet the April 30, 2026, deadline for releasing its audited annual report, requiring more time for the audit process.

Expected Suspension: Consequently, trading in CapAI shares is expected to be suspended starting May 1, 2026, pending the publication of these results, which are expected by the end of June 2026.

I have just been offered 1.611p for a 200K dummy sell.

On a very positive note, whenever I google Author 42 nowadays, I am linked directly to our product. Other links on the same search are connected to earlier articles and announcements about our Author 42.

In my view this is a sure sign of the good progress being made by the company. Just a few weeks ago, a similar search offered books, movies and games incorporating the product name, with nothing whatsoever to do with CapAI’s Author 42.

It definitely feels as if we have liftoff here, although a positive update from the company would add reassurance. Who knows, when the full suite of related products emerges, we may even have a moonshot on our hands?

GLA.

@Alboumphoto

Good point, which I am aware of. This is why I want to know if “growth hacking”, a low cost strategy, is being used to raise awareness of, and promote CapAI’s products?

It doesn’t appear that Claire Lu or Claire L., as she is now known, is involved in her (perhaps?) former roles as Author 42 writing assistant, and growth hacker? Her modified profile suggests that she remains active in that line of work.

Hopefully, the follow up news from last week’s developments will clarify matters? In particular, initial sales and revenue data would give us some idea as to how product sales are progressing?

Following the recent RNS and e-mail, I would like to know how CapAI will market Author 42, and their subsequent products once they are launched?

Last year we were informed that Claire Lu had been assigned the role of “growth hacker”. More recently, Claire has altered her LinkedIn profile to Claire L., and has removed all traces of her previous training, and association with R42 and in particular Author 42.

I believe that Prof Nag has also mentioned a growth hacking app, which is under development at R42?

Jayne Lytel and her team have developed Author 42, a versatile product with a useful toolbox of apps to assist authors of various book genres. We have been informed of two further associated products, which could be used in conjunction with Author 42 or independently in their own right.

I would like to know if growth hacking is part of Author 42’s marketing strategy or whether a growth hacking application is another R42 product, or maybe both? Frankly, I am confused about this, although it ( growth hacking) seemed to be an important part of CapAI’s strategy when it was first mentioned?

GLA.